RICE (US) — Chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell.
The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.
RICE (US) — Chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell.
The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.
RICE (US) — Chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell.
The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.
RICE (US) — Chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell.
The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.
PURDUE (US) — The first fluorescence-guided surgery on an ovarian cancer patient was performed using a cancer cell “homing device” and imaging agent.
The surgery was one of 10 performed as part of the first phase of a clinical trial to evaluate a new technology to aid surgeons in the removal of malignant tissue from ovarian cancer patients. The method illuminates cancer cells to help surgeons identify and remove smaller tumors that could otherwise be missed.
MicroRNAs (miRNA) were discovered that can serve as biomarkers or treatment targets for ovarian cancer. A method was developed to isolate RNA from serum samples and perform a real-time PCR-based microarray for miRNAs using a small sample of serum RNA. RNA was isolated from the serum of patients with ovarian cancer. MicroRNAs (miRNA) were amplified by real-time PCR-based microarray and analyzed. Five miRNAs were overexpressed and three miRNAs were under-expressed in the serum of ovarian cancer patients compared to normal controls. Some of the overexpressed miRNAs are known oncogenes that have therapeutic and biomarker potential.